Professor David Kerr CBE

Supernumerary Fellow

David contributes to Oxford as Professor of Cancer Medicine, where he has worked with colleagues to build a new Institute for Cancer Medicine and Cancer Hospital. He is also Adjunct Prof of Medicine at Weill-Cornell College of Medicine, NY and Honorary Professor of Oncology at the 2nd Military University, Shanghai and Xiamen University.  He has an international reputation for the treatment of and research into colorectal cancer and the quality of his work has been recognised by the award of several international prizes and the first NHS Nye-Bevan award for innovation. He has published over 400 papers and has an H-Index of 80 associated with over 25,000 citations. He has founded 3 University spin outs; COBRA therapeutics, Celleron Therapeutics and Oxford Cancer Biomarkers. He has made a significant contribution to reforming the NHS as a Founding Commissioner for Health Improvement; Chair of the National Cancer Services Collaborative, Instigator of the Department of Health’s networked approach to clinical cancer research and developed a 20 year plan for the future of the NHS in Scotland, the “Kerr Report”.  He was elected Fellow of the Academy of Medical Sciences in 2000, Honorary Fellow of Royal College of General Practitioners in 2007, appointed Commander of the British Empire in 2002 by HM the Queen and was elected President of the European Society of Medical Oncology in 2010. He has established INDOX and Afrox to improve the quality of cancer care in India and Sub Saharan Africa and has served as Health Adviser to two British Prime Ministers, Tony Blair and David Cameron.

 

Contact Details